From hit to lead with in vitro assay development services

The proper combination of in vitro assays can deliver critical information delivering insights that serve as better predictors for the transition to in vivo studies. Charles River in vitro assay development services provides in vitro studies for identification, characterization and validation for both small and large molecules for a variety of diseases.

Capabilities include:

  • Human Primary Cell-Based Assays – Translational cell-based assays from simple cell proliferation and viability assays to multicellular biochemical and functional assays for high content phenotypic screening using human primary cells from tissue, blood and differentiated stem cells
  • In Vitro Oncology Assays – With 80 proprietary cell lines derived from our portfolio of PDX models and over 200 commercial human tumor cell lines available, we offer you the opportunity to test your compound with an extensive screening approach for up to 50 cell lines.
  • In Vitro Immuno-Oncology Assays – Exploit the complex TME with developed single cell and co-culture assays to monitor an immunotherapeutic’s interaction with specific cell types such as T cells, natural killer cells, macrophages, dendritic cells, neutrophils, and fibroblasts.
The Power of In Vitro Assays in Immuno-Oncology

Charles River in vitro assay development services provides in vitro studies for identification, characterization and validation for both small and large molecules for a variety of diseases.The combination of translatable in vitro and in vivo assays, coupled with expertise in immunology and oncology helps facilitate the progression of novel oncology therapeutics from hit identification to investigational new drug submission.
Read the Article

  • In Vitro Immunology Assays – Validated models for eve or articlery cell in the immune system, and those cells which interact with it. This level of expertise is what enables our dedicated analytical and cell biology teams to run assays using primary cells that closely mimic human biology and are suitable for immunology drug screening programs.
  • Antiviral and Antimicrobial Testing – Our combined infection and analytical expertise provides our clients with the most robust portfolio of antiviral and antimicrobial in vitro assays.
  • In Vitro Assays for Amyotrophic Lateral Sclerosis – Using established cultures of human pluripotent stem cell-derived motor neurons amenable to high-throughput screening.
  • In Vitro Assays for Duchenne Muscular Dystrophy – Utrophin Quantification in vitro assay high content imaging of myoblast to myotube differentiation in vitro assay
  • In Vitro Neuroscience Assays and Models – Phenotypic assays using various neuronal cell models for clinically relevant data, by using human ES cells and iPS-derived neurons from patient samples.
  • Ion Channel Screening – Discover novel ion channel therapeutics studying ion channel selectivity profiling in vitro assay, trafficking in vitro assays and epithelial short circuit current in vitro assays.
  • Mechanism of Action Studies – Using its adenoviral technology to elucidate the mechanism of action of small molecules by combining the compound of interest with knockdown or overexpression of candidate gene in the same phenotypic assay.
  • Genome Engineering Techniques – Applying genome engineering techniques to many phases of drug development – from target discovery (e.g., monitoring the loss-of or gain-of function screening using CRISPR gRNA libraries [pooled or arrayed]) to target validation (e.g., evaluating the effect of target knock-outs).